Obsessive-compulsive disorder, 5-HTTLPR polymorphism and treatment response

被引：59

作者：

Di Bella D. ^{[1
]}

Erzegovesi S. ^{[1
]}

Cavallini M.C. ^{[1
]}

Bellodi L. ^{[1
]}

机构：

[1] Fond. Ctr. San Raffaele Monte Tabor, San Raffaele Vita-Salute University, Department Neuropsychiatric Sciences, 20127 Milan

来源：

The Pharmacogenomics Journal | 2002年 / 2卷 / 3期

关键词：

Fluvoxamine; Pharmacogenetics; Serotonin; Serotonin reuptake inhibitors; Tic disorder;

D O I：

10.1038/sj.tpj.6500090

中图分类号：

学科分类号：

摘要：

Recently, a role for a functional polymorphism within the promoter region of the serotonin transporter gene (5-HTTLPR) in conferring susceptibility to Obsessive Compulsive Disorder (OCD) has been suggested. The aim of this study was to test the hypothesis that allelic variation of the 5-HTTLPR could be associated with OCD susceptibility or influence the drug response in OCD. One hundred and eighty-one OCD patients were recruited; 92 patients underwent a standardized treatment with fluvoxamine. No significant differences in allele/genotype distribution of the 5-HTTLPR were found between 191 controls and OCD. No differences in fluvoxamine response in the three genotypes groups in OCD were found, considering Yale-Brown Obsessive Compulsive Scale (YBOCS) total scores. Nevertheless, a significant time per genotype interaction was found for the YBOCS subtotal compulsion scores. Considering patients without tic disorder co-diagnosis, a significant time per genotype, interaction for both YBOCS total scores and compulsion scores was found.

引用

页码：176 / 181

页数：5

共 42 条

[31]

Tollefson G.D., Rampey A.H. Jr., Potvin J.H., Jenike M.A., Rush A.J., Et al., A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder, Arch. Gen. Psychiatry, 51, pp. 559-567, (1994)

[32]

Greist J., Chouinard G., DuBoff E., Halaris A., Kim S.W., Koran L., Et al., Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder, Arch. Gen. Psychiatry, 52, pp. 289-295, (1995)

[33]

Blier P., de Montigny C., Possible serotonergic mechanisms underlying the antidepressant and anti-obsessive-compulsive disorder responses, Biol. Psychiatry, 44, pp. 313-323, (1998)

[34]

(1994)

[35]

Robins L.N., Helzer J.E., Cottler L., (1989)

[36]

Goodman W.K., Price L.H., Rasmussen S.A., Mazure C., Fleishmann R.L., Hill C.L., Et al., The Yale-Brown Obsessive Compulsive Scale, I: Development, use and reliability, Arch. Gen. Psychiatry, 46, pp. 1006-1011, (1989)

[37]

Andreasen N.C., Endicott J.R., Winokour J., The family history method using diagnostic criteria: Reliability and validity, Arch. Gen. Psychiatry, 34, pp. 1229-1235, (1977)

[38]

McDougle C.J., Goodman W.K., Leckman J.F., Lee N.C., Heninger G.R., Price L.H., Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind placebo-controlled study in patients with and without tics, Arch. Gen. Psychiatry, 51, pp. 302-308, (1994)

[39]

Mundo E., Bianchi L., Bellodi L., Efficacy of fluvoxamine, paroxetine and citalopram in the treatment of obsessive-compulsive disorder: A single-blind study, J. Clin. Psychopharmacol, 17, pp. 1-5, (1997)

[40]

Lucca A., Lucini V., Catalano M., Alfano M., Smeraldi A., Plasma tryptophan to large neutral amino acids ratio and therapeutic response to a selective serotonin uptake inhibitor, Neuropsychobiology, 29, pp. 108-111, (1994)

← 1 2 3 4 5 →